First Follow up Response Evaluation of Conventional vs Drug Eluting Bead Transarterial Chemo Embolization: A Comparative Study at Tertiary Care Radiology Centre, Rawalpindi
Abstract
Objective: To compare treatment with drug eluting beads Transarterial Chemoembolization (DEB TACE) vs
Conventional Transarterial chemoembolization (cTACE) in hepatocellular carcinoma (HCC) patients at first
follow up.
Study Design: Comparative Interventional Study.
Place and Duration of Study: The study was conducted in the department of Radiology CMH Rawalpindi
and Armed Forces Institute of Radiology and Imaging (AFIRI), Rawalpindi from July 2015 to May 2019.
Materials and Methods: 254 patients were included in the study. Conventional TACE was done on 176 patients
and DEB TACE was done on 78 patients. All patients were called for follow up after 06 weeks. First response
evaluation of treated lesions in these patients was seen on triphasic CT liver after 06 weeks of TACE therapy.
Results: On first follow up, out of 176 patients with cTACE, 'Total response' was seen in 90(51.1%) patients,
'Partial response' in 76 patients (43.1%),'No response' in 04(2.27%) patients.' Progressive disease' was seen in
06(3.4%) patients.
DEB TACE was done in 78 patients. Out of these, 27 (34.6%) patients showed 'Total response'. 50(64.1%)
patients showed 'Partial response', 'Progressive disease' was seen in one patient (.02%).
Conclusion: The findings of this study have shown that c TACE has a better outcome regarding first response
evaluation. 'No response' to treatment was not seen in any patient with DEB TACE.
References
Butt AS, Abbas Z, Jafri W. Hepatocellular Carcinoma in Pakistan: Where do We Stand? Hepatitis Monthly. 2012; 12: e6023.
Parkash O, Hamid S. Next big threat for Pakistan hepatocellular carcinoma (HCC). Journal of Pakistan
Medical Association. 2016; 66: 735-9.
Dinca H, Pelage JP, Baylatry MT, Ghegediban SH, Pascale F, Manfait M. Why do small size doxorubicin-eluting
microspheres induce more tissue necrosis than larger ones? A comparative study in healthy pig liver (oral
communication 2206-2). CIRSE Annual meeting, Lisbon 2012.
Prajapati HJ, Xing M, Spivey JR, Hanish SI, El-Rayes BF, Kauh JS, et al. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC. American Journal of Roentgenology. 2014; 203: W706-14.
Lee Y, Jung K, Kim D, Choi J, Kim B, Kim S, et al. Conventional versus drug-eluting beads chemoembolization for
hepatocellular carcinoma: Emphasis on the impact of tumor size. Journal of Gastroenterology and Hepatology. 2017; 32: 487-96.
Zou JH, Zhang L, Ren ZG, Ye SL. Efficacy and safety of c TAC Ever sus DEB-TACE in patients with hepatocellular
carcinoma: a meta-analysis. Journal of Digestive Diseases. 2016; 17: 510-17.
Gao S, Yang Z, Zheng Z, Yao J, Deng M, Xie H, et al. Doxorubicin-eluting bead versus conventional TACE for
unresectable hepatocellular carcinoma: a meta-analysis. Hepato-gastroenterology. 2013; 60: 813-20.
Huang K, Zhou Q, Wang R, Cheng D, Ma Y. Doxorubicineluting beads versus conventional transarterial
chemoembolization for the treatment of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology.
; 29: 920-5.
Xie Z, Wang X, Peng Y, Zhu S, Ma L, Xiang B, et al. Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma. Hepatology Research. 2014; 45: 190-200.
Song JE, Kim DY. Conventional vs drug eluting beads transarterial chemo embolization for hepatocellular
carcinoma.World J Hepatol. 2017; 9: 808-14.
Song MJ, Chun HJ, Kim HY, Yoo SH, Park CH, Bae SH, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. Journal of
hepatology. 2012; 57: 1244-50.
Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current
state of the art. World Journal of Gastroenterology. 2018; 24: 161-9.
Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of
d o x o r u b i c i n - e l u t i n g b e a d s v s c o n v e n t i o n a l chemoembolisation for hepatocellular carcinoma. British Journal of Cancer. 2014; 111: 255-64.
Li H, Wu F, Duan M, Zhang G. Drug eluting bead transarterial chemoembolization (TACE) vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE history. A comparison of efficacy and safety. Medicine: 2019; 98: e15314.
